PDCD1 and non-small cell lung carcinoma: Similarly, Kitagawa et al. reported an ORR of 5.9% among 17 NSCLC patients undergoing interchange between anti-PD-1 (nivolumab and pembrolizumab) and anti-PD-L1 (atezolizumab) as rechallenge therapy, where 41.2% of cases showed PD-L1 expression greater than 1% [16].